Inactivating PHEX (phosphate regulating gene with homologies to endopeptidases on the X chromosome) mutations cause X-linked hypophosphatemia in humans and mice (Hyp) through overproduction of fibroblast growth factor 23 (FGF23) a phosphaturic factor, by osteocytes. Matrix extracellular phosphoglycoprotein (MEPE) is also elevated in Hyp and other hypophosphatemic disorders. In addition, the administration of an ASARM (acidic serineaspartate rich MEPE-associated motif) peptide derived from MEPE causes phosphaturia and inhibits bone mineralization in mice, suggesting that MEPE also plays a role in phosphate homeostasis. Since recent studies found that MEPE binds specifically to PHEX in vitro, we tested the effect of recombinant-MEPE and its ASARM peptide on PHEX enzyme activity in vitro and FGF23 expression in bone marrow stromal cell cultures ex vivo. We found that both recombinant MEPE and synthetic phosphorylated ASARM peptide (ASARM-PO 4 ) inhibit PHEX enzyme activities in an in vitro fluorescent-quenched PHEX enzyme activity assay. The ASARM-PO 4 peptide inhibits PHEX enzyme activity in a dose-dependent manner with a K i of 128 nM and V maxKi of 100%. Recombinant MEPE also inhibits PHEX activity (K i Z2 nM and V maxKi Z26%). Long-term bone marrow stromal cell cultures supplemented with 10 mM ASARM-PO 4 peptide resulted in significant elevation of FGF23 transcripts and inhibition of mineralization. These findings suggest that MEPE inhibits mineralization and PHEX activity and leads to increased FGF23 production. The resulting coordination of mineralization and release of a phosphaturic factor by MEPE may serve a physiological role in regulating systemic phosphate homeostasis to meet the needs for bone mineralization.
Introduction
Fibroblast growth factor 23 (FGF23) is a novel phosphaturic hormone (Econs & Drezner 1994 , ADHR Consortium 2000 , Shimada et al. 2001 ) predominately produced by osteocytes in bone (Liu et al. 2006b ). FGF23 regulates serum phosphate levels by inhibition of renal phosphate reabsorption and by suppression of 1,25(OH) 2 D 3 production by the kidney. Overexpression of FGF23 causes hypophosphatemia and reduced 1,25(OH) 2 D 3 levels and rickets/osteomalacia (Bai et al. 2004 , Larsson et al. 2004 , Shimada et al. 2004b . In contrast, FGF23 deficiency (Bai et al. 2003 , Shimada et al. 2004a , Liu et al. 2006b or mutations increasing FGF23 degradation (Larsson et al. 2005 ) results in hyperphosphatemia, increased serum 1,25(OH) 2 D 3 levels, and soft tissue calcifications. FGF23 is a pathological phosphaturic factor in several hereditary hypophosphatemic disorders, including X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR). XLH is caused by inactivating mutations of PHEX (phosphate regulating gene with homologies to endopeptidases on the X chromosome; The HYP Consortium 1995), a member of the M13 family of the type II cell-surface zinc-dependent proteases (Rowe et al. 1997) . Serum levels of FGF23 are elevated in XLH (Yamazaki et al. 2002 , Weber et al. 2003 and Hyp mice , the murine homologue of XLH. FGF23 is not the substrate for PHEX , Benet-Pages et al. 2004 ; instead loss of PHEX function results in overproduction of FGF23 by osteocytes in bone through mechanisms that remain to be defined (Liu et al. , 2006c . ADHR is caused by mutations that prevent the degradation of FGF23 (White et al. 2001) .
Matrix extracellular phosphoglycoprotein (MEPE) is a member of the SIBLING protein family (Fisher & Fedarko 2003) originally cloned from a patient with tumor-induced osteomalacia (TIO) (Rowe et al. 2000) . MEPE is exclusively expressed in osteoblasts, osteocytes, and odontoblasts and markedly up-regulated in Hyp osteoblasts and TIO tumors (Petersen et al. 2000 , Rowe et al. 2000 , Argiro et al. 2001 , Guo et al. 2002 , Fisher & Fedarko 2003 , Gowen et al. 2003 . MEPE was originally proposed as candidate for the phosphaturic factor in TIO; however, MEPE deficiency results in accelerated osteoblast-mediated bone formation and mineralization without changes in serum phosphate levels (Gowen et al. 2003 , Liu et al. 2005b . These findings suggest that its primary function is to regulate the mineralization process, although administration of recombinant MEPE is reported to induce phosphaturia in mice ). In addition, MEPE can be cleaved by cathepsin B to release a carboxy-terminal MEPE peptide (ASARM peptide) ) and the phosphorylated ASARM peptide inhibits mineralization in vivo and in vitro and binds to PHEX (Rowe et al. , 2005 , suggesting that MEPE also undergoes proteolytic processing.
MEPE is elevated in the bone of Hyp mice and positively correlated with FGF23 expression (Weber et al. 2003 , Liu et al. 2005b ), but the relationship between PHEX and MEPE is not clear. Similar to its proposed role in TIO, MEPE was also thought to be a candidate for the phosphaturic factor in XLH/Hyp. However, we have recently demonstrated that the Hyp phosphaturic phenotype is not corrected by transfer of MEPE-deficient mice on to the Hyp mouse background (Liu et al. 2005b) , indicating that MEPE is not the phosphaturic factor in this disorder. While these studies indicate that MEPE is not the proximate cause of hypophosphatemia in Hyp mice, it does not preclude an upstream effect of MEPE that is potentially mediated through MEPE binding to PHEX via the MEPE ASARM-motif or a role of MEPE in the mineralization defect in Hyp mice (Rowe et al. 2005) .
To further understand the relationship between PHEX, MEPE, and FGF23 in causing hypophosphatemia, we tested the ability of recombinant-MEPE and ASARM peptides to inhibit PHEX enzyme activity in vitro. We also determined whether MEPE and ASARM-PO 4 peptides were able to up-regulate FGF23 expression and inhibit mineralization in a bone marrow stromal cell culture system.
Materials and Methods

Assay of SecPHEX endopeptidase activity
A quenched fluorescence enzymatic assay used to measure PHEX endopeptidase activity was kindly offered by Dr Philippe Crine from Enobia Inc., Montreal, Canada (Campos et al. 2003) . In this assay, a secreted form PHEX (SecPHEX) and a synthetic substrate (Abz)-GFSDYK-(Dnp) were used. The synthetic peptide substrate was labeled with a fluorogenic reagent aminobenzoic acid (Abz) in the amino terminus and a quenching moiety dinitrophenyl (Dnp) in the carbonic terminus. The secPHEX dose-dependent activity was tested from concentrations of 10 to 100 ng with 10 mM substrate. The reaction was followed by measuring the fluorescence from excitation at 320 nm and emission at 420 nm in a Synergy HT Multi-Detection Microplate Reader (BioTek Instruments, Inc., Winooski, VT, USA). Full-length insect expressed human MEPE was purified and expressed as described previously (Rowe et al. , 2005 . Synthetic peptides derived from MEPE sequence, including MEPEarginine glycine aspartate motif (RGD) peptide, phosphorylated ASARM (ASARM-PO 4 ), and non-phosphorylated ASARM peptide (Multiple Peptide Systems, Inc., San Diego, CA, USA) were used in the inhibition assay (Rowe et al. 2005) . PHEX activities were expressed as an initial speed rate calculated by fitting the steepest linear slope over at least eight adjacent reading values. The slope was converted into nanomoles of substrate hydrolyzed per minute and kinetic parameters, K i and V maxKi , were calculated by the non-linear regression data analysis GraphPad Prism 4 software (GraphPad Software, Inc., San Diego, CA, USA).
Animal care and genotyping
The FGF23-deficient/reporter mouse model was created by knocking in an enhanced green fluorescent protein (eGFP) construct following the adenine thymine guanine (ATG) in exon 1 of the FGF23 gene as previously reported (Liu et al. 2006b ) and was crossed and maintained on C57BL/6J background. This eGFP reporter mouse was also transferred onto Hyp background. The heterozygous FGF23-deficient/ reporter mouse will express eGFP under control of endogenous FGF23 promoter and mimic the expression pattern of FGF23. Genomic DNA tissue was extracted and purified from the tail of each mouse using a QIAGEN DNeasy Tissue Kit (QIAGEN Inc). Genotypes were determined by PCR as previously reported (Liu et al. 2006b ).
All mice were fed with a standard rodent diet (8604 Harlan NIH 86-23, 1985) .
Bone marrow stromal cell (BMSC) culture
BMSCs from long bones isolated from 6-to 8-week-old male FGF23-deficient/eGFP reporter mice on both wildtype (WT) and Hyp background were cultured as previously described (Liu et al. 2006b ). Briefly, bone marrow cells were isolated and plated in 35 mm dishes at a density of 7!10 6 per 35 mm plate and grown in 2-minimum essential medium (a-MEM; Invitrogen) containing 10% fetal bovine serum (FBS) for 5 days and then switched to the differentiation medium (a-MEM containing 10% FBS supplemented with 5 mmol/1, b-glycerophosphate, and 25 mg/ml ascorbic acid) with and without phosphorylated ASARM peptide at 10 mM concentration. At day 14, pictures of the cells were taken under bright field and fluorescent light microscopy. Cells were then either stained with Alizarin red-S or used for RNA extraction. Alizarin red-S stain was extracted with 10% cetylpyridinium chloride and quantified by absorbance measurement at 562 nm as previously described (Liu et al. 2005a) .
RNA isolation and quantitative RT-PCR
Total RNAs were extracted from cultured cells with Trizol (Invitrogen) and then treated with RNase-free DNase using an RNeasy column (QIAGEN Inc.). First strand cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad). Total RNA (1 mg) was used in each 20 ml reverse transcription reaction. Input RNAs (400 and 20 ng) were used to amplify FGF23 and cyclophilin A respectively. The primers used for real-time quantitative RT-PCR are 5 0 -TGTCGCAGAAG-CATCA-3 0 and 5 0 -GTGGGCGAACAGTGTAGAA-3 0 for FGF23 and 5 0 -CTGCACTGCCAAGACTGAAT-3 0 and 5 0 -CCACAATGTTCATGCCTTCT-3 0 for cyclophinin A. The iCycler iQ Real-Time PCR Detection System and iQ SYBR Green Supermix (Bio-Rad) were used for real-time PCR analysis as previously reported (Liu et al. 2006b ).
Results
Recombinant MEPE and ASARM-PO 4 inhibit PHEX enzyme activities
To evaluate the functional significance of our previously reported MEPE and MEPE ASARM-peptide (phosphorylated and non-phosphorylated) interactions with PHEX (Rowe et al. 2005) , we examined if addition of recombinant MEPE or its ASARM peptide (phosphorylated and nonphosphorylated) inhibited PHEX enzymatic activity in vitro. For these studies, we used the previously reported soluble secreted recombinant PHEX enzyme and a synthetic fluorescent-quenched peptide that is specifically cleaved by PHEX (Campos et al. 2003) . We found that both recombinant MEPE (Fig. 1) and synthetic phosphorylated ASARM peptide (ASARM-PO 4 ; Fig. 2 ) inhibit PHEX enzyme activities. Recombinant full-length MEPE significantly inhibited PHEX activity at concentrations of 2 nM in a dose-dependent and saturable manner. The K i and V maxKi were 2 nM and 26% respectively (Fig. 1) . Synthetic ASARM-PO 4 peptide (derived from the C-terminal MEPE ASARMmotif) also resulted in a potent inhibition of PHEX activity in vitro with a K i and V maxKi of 129 nM and 100% respectively (Fig. 2) . Specifically, dose-, time-dependent, and saturable inhibition of PHEX activity was observed at nM concentrations for both recombinant MEPE and ASARM-PO 4 . Control RGD peptide (Fig. 2) and non-phosphorylated ASARM peptide (data not shown) had no effect on PHEX activity at micromolar levels. The inhibitory effects of MEPE and ASARM-PO 4 on PHEX enzyme activity are consistent with previously reported surface plasmon resonance binding studies (Rowe et al. 2006) .
ASARM-PO 4 stimulates FGF23 transcript and inhibits mineralization in BMSC cultures
Next, we explored whether ASARM-PO 4 inhibition of PHEX activity has biological significance. To evaluate the effects of ASARM-PO 4 on FGF23 production by osteoblasts, we incubated 10 mM ASARM-PO 4 with BMSCs derived from FGF23-deficient/eGFP reporter mice, which express eGFP under the control of the endogenous FGF23 promoter. For controls, we assessed BMSCs not treated with peptide (normal controls) and BMSCs from Hyp mice (positive controls), which are PHEX deficiency and exhibit elevated FGF23 expression (Liu et al. 2006b ). Incubation of these cells for 14 days in the presence of 10 mM ASARM-PO 4 peptide resulted in a significant twofold increase in FGF23 mRNA levels compared with untreated control cultures (Fig. 3A) . In addition, ASARM-PO 4 peptide increased eGFP expression that was limited to osteocytes embedded in mineralization nodule (Fig. 3B) . However, the level of FGF23 expression was less than observed in Hyp controls. The addition of the ASARM-PO 4 peptide also inhibited mineralization, as evidenced by alizarin red-stained nodules in ASARM-PO 4 peptide-treated BMSCs compared with untreated controls (Fig. 4A) . In contrast to the attenuated reduction in FGF23, ASARM-PO 4 inhibited mineralization to a similar degree as Hyp-derived BMSCs (Fig. 4B ).
Discussion
Our findings provide new insights into how PHEX, MEPE, and FGF23 potentially act in concert to regulate phosphate homeostasis and matrix mineralization. First, the ability of MEPE and the MEPE-derived ASARM-PO 4 peptide to inhibit PHEX activity in vitro (Fig. 2) , and stimulate FGF23 production by BMSC (Fig. 3) , suggests that MEPE is an important regulator of PHEX function. In previous studies, we have shown that PHEX inhibits MEPE degradation in vitro (Guo et al. 2002) and that MEPE and its ASARM-PO 4 peptide binds to the PHEX protein catalytic site (Rowe et al. 2005 ). The present findings support the possibility that the observed phosphaturic effects of MEPE in vivo are mediated, at least in part, through MEPE binding to and inactivation of PHEX. Both the ASARM-PO 4 peptide and MEPE maximally inhibit PHEX activity at nanomolar concentrations, in a dose-dependent and saturable manner (maximal inhibition 100% for ASARM-PO 4 and 25% for MEPE). Recent detection of micromolar levels of circulating MEPE (Bresler et al. 2004 , Jain et al. 2004 suggests that the inhibition of PHEX represents a physiological concentration of MEPE. The observation that the phosphorylated ASARM peptide is more potent than full-length MEPE also raises the possibility that proteolytic processing and phosphorylation are important means to . RGD and non-phosphorylated ASARM control peptides had no effect on enzyme activity up to micromolar concentrations (data not shown). ASARM-PO 4 inhibited secPHEX activity in a dose-dependent and saturable manner with a maximum inhibition (V maxKi ) of 100% and a K i of 128 . 7 nM. Each experimental dose point is statistically significant by one-way ANOVA analysis at P value !0 . 05.
regulate the biological functions of MEPE (Rowe et al. , 2005 . Recently, the importance of proteolytic processing in Hyp has been shown by the improved bone mineralization following the in vivo administration of cathepsin inhibitors (Rowe et al. 2006) . Secondly, we confirm the ability of the ASARM-PO 4 peptide to regulate mineralization. We found that the addition of ASARM-PO 4 peptide, in physiological concentrations, inhibited mineralization of BMSC cultures (Fig. 4) . The MEPEderived ASARM-PO 4 peptide has also been shown to inhibit mineralization in vivo in mice and in vitro using a murine osteoblast cell-line (2T3 cells; Rowe et al. 2004 Rowe et al. , 2005 . Our prior observations also implicate MEPE in the mineralization defect observed in Hyp mice. In this regard, mineralization of BMSC cultures is improved in MEPE-deficient Hyp mice ex vivo, in spite of persistent hypophosphatemia in the combined MEPE-deficient/Hyp mice (Liu et al. 2005a,b) . The increased MEPE in Hyp mouse bone could account for the 'intrinsic' mineralization abnormality in this disorder. Thus, MEPE and/ or its degradation products may directly interfere with the process of mineralization of the extracellular matrix independent of hypophosphatemia. The exact mechanism whereby the mineralization process is disrupted by the ASARM peptide, and the role of PHEX/MEPE interactions in the process, is not clear, but likely involves altering the ratio of inhibitors and/or inducer of mineralization (Murshed et al. 2005) . Although we demonstrate that MEPE and its ASARM peptide inhibit PHEX activity in vitro and is associated with increased FGF23 message expression in culture, our studies have not established that the reported phosphaturic actions of MEPE ) are mediated through increased FGF23 or inhibition of PHEX in vivo. Future studies that investigate whether FGF23-null mice are refractory to MEPE-induced phosphaturia would be necessary to establish the role of FGF23 in mediating MEPE actions. MEPE inhibition of PHEX, if physiologically relevant, places MEPE upstream of PHEX. This might explain not only the phosphaturic effect of recombinant MEPE, since excess MEPE would mimic the effects of inactivating PHEX mutations in Hyp, but potentially also explain why superimposed MEPE deficiency failed to rescue the Hyp phenotype (Liu et al. 2005b) . It is also possible that MEPE has effects that are independent of both FGF23 and PHEX both in bone and other sites.
Regardless, phosphate is an important determinant of mineralization of extracellular matrix in bone and soft tissues (Murshed et al. 2005 ) and a bone-kidney axis involving PHEX and FGF23 may regulate renal phosphate handling to meet the demand of phosphate for mineralization of bone (Quarles 2003 , Liu et al. 2006a . Our findings of the dual regulation of PHEX and mineralization by MEPE degradation products suggest that MEPE may also be involved in this putative bone-kidney axis as an intermediate molecule in bone matrix that directly regulates the mineralization process in bone and indirectly coordinates renal phosphate handling through interactions with PHEX and regulation of FGF23 production. Proof of this hypothesis will require additional studies that establish the respective roles of PHEX and FGF23 in mediating the effects of MEPE in vivo. 
